Table 3.
Baseline Disease Characteristics
| Characteristic | No. | % |
|---|---|---|
| FIGO stage | ||
| I-C | 1 | 3.3 |
| II-A | 1 | 3.3 |
| II-C | 1 | 3.3 |
| III-A | 1 | 3.3 |
| III-B | 1 | 3.3 |
| III-C | 18 | 60.0 |
| IV | 7 | 23.3 |
| Cell type | ||
| Serous | 23 | 76.7 |
| Adenocarcinoma, NOS | 3 | 10.0 |
| Clear cell | 2 | 6.7 |
| Mixed epithelial | 1 | 3.3 |
| Undifferentiated | 1 | 3.3 |
| Tumor grade | ||
| 3 | 29 | 96.7 |
| Unknown | 1 | 3.3 |
| No. of prior regimens | ||
| 1 | 16 | 53.3 |
| 2 | 14 | 46.7 |
| Most recent platinum sensitivity | ||
| PFI < 6 months | 22 | 73.3 |
| PFI ≥ 6 months | 8 | 26.7 |
Abbreviations: FIGO, International Federation of Gynecology and Obstetrics; NOS, not otherwise specified; PFI, platinum-free interval.